- Atlas
- Medicine & Health
- Nephrology
Nephrology
Nephrology Nephrology is the branch of internal medicine that deals with the kidneys: how they filter blood, balance water and salts, regulate acid and blood pressure, and signal to the bone marrow and skeleton; and what happens when they fail.
10 frameworks, from 1827 to today · Internal Medicine · Medicine & Health
- Clinical Syndromic Diagnosis 1827-Present
- Filtration–Reabsorption Physiology 1840-Present
- Hemodialysis as Chronic Care 1943-Present
- Electrolyte and Acid–Base Physiology and Management 1950-Present
- Immune-Mediated Glomerulonephritis 1950-Present
- Renal Pathology and Biopsy-Based Classification 1950-Present
- Transplant Immunology and Immunosuppression 1954-Present
- Peritoneal Dialysis 1960-Present
- Organ-Protective Pharmacotherapy 1990-Present
- CKD Staging and Epidemiology 2002-Present
Overview
Nephrology
Nephrology is the branch of internal medicine that deals with the kidneys: how they filter blood, balance water and salts, regulate acid and blood pressure, and signal to the bone marrow and skeleton; and what happens when they fail. The stakes are unusually high for a small pair of organs. Untreated kidney failure is fatal within weeks, and the treatments that keep people alive without working kidneys—dialysis and transplantation—are among the most demanding and expensive in medicine. The field's history is largely the story of three problems: understanding what the kidney actually does, learning to see kidney disease in tissue and in numbers, and building machines and immune strategies that can stand in for, or replace, a failed organ.
The Kidney as a Filter: Physiology and Clearance
Nineteenth-century anatomy had already mapped the kidney's architecture—the glomerulus (the tuft of capillaries where blood is filtered), the tubules, and the looped structures named for their describer—but the organ's purpose was contested. Some held that the kidney secreted urine the way a gland secretes saliva; others that it filtered blood under pressure. The Scottish physician William Bowman described the capsule at the start of the glomerulus in 1842, and the German anatomist Carl Ludwig argued in the 1840s for a filtration–reabsorption model: water and small solutes are forced through the glomerular wall, and the tubules take back what the body needs. The competing secretory view was not fully displaced until the twentieth century.
The decisive tool was clearance. Clearance is the volume of blood plasma completely cleared of a substance per unit time; if a substance is filtered freely and neither reabsorbed nor secreted, its clearance measures the filtration rate. In the 1920s and 1930s, the American physiologist Homer Smith and colleagues used inulin—a plant carbohydrate filtered freely and handled by the kidney in exactly that way—to measure glomerular filtration rate (GFR) in humans. Clearance gave the kidney a measurable number, and with it a way to stage disease. The Danish physiologist Poul Brandt Rehberg had earlier used creatinine, a muscle waste product, for the same purpose; creatinine clearance remains the everyday clinical proxy because it needs only a blood and urine sample. The later refinement—estimating GFR from a blood creatinine level plus age, sex, and other variables, without any urine collection—turned kidney function into a routine laboratory number.
Clinical Syndromes and the Birth of a Specialty
Before there were treatments, there were patterns. Nineteenth-century clinicians grouped kidney disease by what the patient looked like: dropsy (swelling from retained fluid), scanty or bloody urine, and the "Bright's disease" complex named after the English physician Richard Bright, who in the 1820s and 1830s linked dropsy and protein in the urine to diseased kidneys seen at autopsy. The French physician Pierre Rayer and others distinguished acute from chronic forms. By the early twentieth century, the field had a working vocabulary of syndromes—nephrotic syndrome (heavy protein loss in the urine, low blood albumin, swelling), nephritic syndrome (blood and protein in the urine with high blood pressure and declining function), acute kidney injury, and chronic kidney failure—that organized clinical care long before the mechanisms were understood. This syndromic approach was the specialty's first operating model: diagnose by pattern, treat the consequences (fluid overload, high potassium, acidosis), and hope the kidney recovered.
The Biopsy and the Classification of Glomerular Disease
The next turning point came from the microscope. Percutaneous kidney biopsy—passing a needle into the kidney to obtain tissue—was developed in the mid-twentieth century, with the Danish physician Poul Iversen and the American Robert Kark among the pioneers in the 1940s and 1950s. Once tissue could be obtained safely, immunofluorescence (using antibodies tagged with a fluorescent dye to show where immune proteins sit in the glomerulus) and electron microscopy added a molecular layer to what light microscopy showed. The result was a classification of glomerular disease built on what the tissue looked like and what was deposited in it: for example, the distinction between minimal change disease (normal-looking glomeruli on light microscopy, foot-process fusion on electron microscopy) and focal segmental glomerulosclerosis; the recognition of IgA nephropathy by the French pathologist Jean Berger in 1968; and the separation of membranous nephropathy, membranoproliferative patterns, and the vasculitic and lupus-associated glomerulonephritides. The biopsy made the diagnosis specific and, crucially, made treatment decisions—steroids, immunosuppressants—testable against a defined lesion rather than a clinical impression.
Immunology Enters the Clinic
The mid-twentieth century also brought the insight that many kidney diseases are immune-mediated. The demonstration that antibodies and immune complexes deposit in the glomerulus, and that some forms of nephritis follow streptococcal infection or accompany systemic lupus, reframed glomerulonephritis as an immunological problem. The discovery of anti-glomerular basement membrane antibodies in Goodpasture's disease (the name honors the American pathologist Ernest Goodpasture, who described the lung–kidney syndrome in 1919) and of antineutrophil cytoplasmic antibodies (ANCA) in the small-vessel vasculitides in the 1980s gave clinicians serological markers and, with them, the rationale for plasma exchange and cytotoxic therapy. The treatment of these diseases—high-dose steroids, cyclophosphamide, later rituximab—was borrowed from oncology and transplant immunology and refined by controlled trials.
Dialysis: From Artificial Kidney to Chronic Care
The first working artificial kidney was built by the Dutch physician Willem Kolff in the occupied Netherlands during the Second World War, using sausage casing as the membrane and a rotating drum; his first patient, in 1943, was treated for acute kidney failure. The device proved that urea and other wastes could be removed from blood outside the body. The problem it could not solve was access: repeated treatment required a way to reach the bloodstream again and again. In 1960 the American physicians Belding Scribner and Wayne Quinton devised the Scribner shunt, a plastic tube connecting an artery to a vein that could be cannulated repeatedly, and chronic hemodialysis became possible. The Seattle program that followed raised the defining ethical question of the era—who gets a scarce life-saving treatment—and the "God committee" that adjudicated access became a landmark in medical ethics. The later arteriovenous fistula, created surgically from the patient's own vessels, gave a more durable and less infection-prone access and remains the preferred route today.
Hemodialysis also became an operating model of care, not just a machine: outpatient units, fixed schedules (typically three sessions a week), vascular-access surgery, dialysis nursing, and the management of anemia, bone disease, and nutrition in people living for years on treatment. Peritoneal dialysis developed in parallel. The peritoneum, the membrane lining the abdominal cavity, can serve as the filtering membrane if dialysis fluid is instilled into the abdomen and drained; the German physician Georg Ganter attempted it in the 1920s, and the technique became practical in the 1960s and 1970s with the development of indwelling catheters (notably by the American physician Henry Tenckhoff) and sterile, bagged solutions. Peritoneal dialysis offered home treatment and preserved residual kidney function, and it became a major modality in many health systems, especially where hemodialysis capacity is limited.
Transplantation and the Control of Rejection
Kidney transplantation is the only treatment that restores full kidney function, and its history is the history of transplant immunology. Early attempts in the first decade of the twentieth century failed because the immune system destroyed the graft. The turning point was the recognition of the immune basis of rejection and the demonstration, by the British biologist Peter Medawar and colleagues in the 1940s and 1950s, that rejection is an immunological process that can be studied and, in principle, suppressed. The first successful kidney transplant between identical twins was performed by Joseph Murray in Boston in 1954, proving that a kidney could function in a new body if the immune barrier were absent1. The discovery of the human leukocyte antigen (HLA) system by Jean Dausset and others in the 1950s and 1960s made matching possible, and the drug azathioprine, used with steroids from the early 1960s, produced the first durable success with unrelated donors. Cyclosporine, introduced in the late 1970s and 1980s, was a genuine revolution: it suppressed T-cell activation selectively enough to prevent rejection without destroying the whole immune system, and it made transplantation a routine rather than experimental therapy. Modern immunosuppression—tacrolimus, mycophenolate, induction antibodies, and regimens tailored to individual risk—descends directly from that line, and the field's persistent problems (chronic graft loss, infection, cancer, and the shortage of organs) are its open questions.
Counting Kidney Disease: Staging and Epidemiology
As dialysis and transplantation became available, medicine needed a way to identify who would need them and when. The answer was a staging system built on GFR. In 2002 the Kidney Disease Outcomes Quality Initiative (KDOQI) of the US National Kidney Foundation published a classification of chronic kidney disease (CKD) into stages 1–5 based on estimated GFR and evidence of kidney damage, with stage 5 corresponding to the threshold for renal replacement therapy. The system was refined and internationally adopted (notably by KDIGO, the Kidney Disease: Improving Global Outcomes initiative) with the addition of albuminuria categories, because protein in the urine predicts progression independently of GFR. Staging did something no previous framework had done: it defined CKD as a population-level condition, not just a set of individual diagnoses, and made it measurable in large cohorts. Epidemiology followed—studies such as the US NHANES surveys and international collaborations established that CKD is common, often unrecognized, and strongly associated with cardiovascular death. The modern understanding that most people with CKD die of cardiovascular disease before reaching dialysis reframed the field's priorities toward early detection, blood-pressure control, and organ-protective drugs.
The Present
Contemporary nephrology rests on all of these foundations at once. Clinical care is organized around estimated GFR and albuminuria staging, biopsy-based diagnosis of glomerular disease, and syndrome-driven management of electrolytes and acid–base disorders—the everyday work of correcting potassium, sodium, and pH that has been the internist's craft since the nineteenth century but is now guided by physiology and measured outcomes. Dialysis is a mature industry with unresolved questions about dose, timing, and patient-reported outcomes; peritoneal dialysis is being re-expanded as a home therapy; and transplantation is limited chiefly by organ supply, with xenotransplantation and machine perfusion under active investigation. The most consequential recent shift is pharmacological: drugs that slow CKD progression by protecting the kidney directly—ACE inhibitors and angiotensin-receptor blockers from the 1990s, SGLT2 inhibitors repurposed from diabetes in the 2010s, and newer agents such as finerenone—have made "slowing progression" a realistic clinical goal rather than a hope. What remains open is the deepest problem the field has carried since Bright: most chronic kidney disease is silent until late, its earliest mechanisms are incompletely understood, and the therapies that work are still unevenly delivered.
References
- Kidney transplantation (introduction, History), Wikipedia
The frameworks of Nephrology
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1827-Present
Clinical Syndromic Diagnosis
What pattern of signs defines this kidney disease?
- 1840-Present
Filtration–Reabsorption Physiology
How does the kidney filter and reabsorb?
- 1943-Present
Hemodialysis as Chronic Care
How can a machine replace kidney function long term?
- 1950-Present
Electrolyte and Acid–Base Physiology and Management
How does the kidney balance salts and acid?
- 1950-Present
Immune-Mediated Glomerulonephritis
How does immune attack damage the glomerulus?
- 1950-Present
Renal Pathology and Biopsy-Based Classification
What does kidney tissue look like under the microscope?
- 1954-Present
Transplant Immunology and Immunosuppression
How can a transplanted organ escape immune rejection?
- 1960-Present
Peritoneal Dialysis
Can the abdominal lining serve as a dialysis membrane?
- 1990-Present
Organ-Protective Pharmacotherapy
Which drugs slow the loss of kidney function?
- 2002-Present
CKD Staging and Epidemiology
How severe is this patient's chronic kidney disease?
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
CKD Staging and Epidemiology grew out of Filtration–Reabsorption Physiology
CKD staging is built directly on the clearance concept: estimated GFR from serum creatinine is the filtration–reabsorption physiology's measurable number, and the stage boundaries are defined by GFR ranges. The staging system generalized clearance measurement into an epidemiological classification.
Carried by Homer Smith.
Filtration–Reabsorption Physiology influenced by Clinical Syndromic Diagnosis
Clinical syndromic descriptions of dropsy and proteinuria, especially Bright's linkage of these to diseased kidneys at autopsy, framed the question of what the kidney does that physiology then answered. The filtration–reabsorption model was built to explain how such clinical patterns arose from organ function.
Carried by Richard Bright; Carl Ludwig.
Hemodialysis as Chronic Care influenced by Clinical Syndromic Diagnosis
The syndromic diagnosis of acute and chronic kidney failure defined the patient group for whom an artificial kidney was built. Kolff's first treatments were aimed at the clinical picture of acute uremia that syndromic diagnosis had delineated.
Carried by Willem Kolff.
Renal Pathology and Biopsy-Based Classification influenced by Clinical Syndromic Diagnosis
Biopsy-based classification was developed to give tissue specificity to the clinical syndromes that had organized nephrology. The syndromes supplied the questions—why does this patient have nephrotic versus nephritic features—that the biopsy was used to answer.
Carried by Robert Kark; Poul Iversen.
CKD Staging and Epidemiology influenced by Clinical Syndromic Diagnosis
The older clinical category of chronic kidney failure supplied the patient concept that CKD staging quantified and stratified. Staging replaced the qualitative syndromic label with GFR-defined stages while keeping the same clinical entity.
Electrolyte and Acid–Base Physiology and Management grew out of Filtration–Reabsorption Physiology
The filtration–reabsorption account of how the tubule handles filtered solutes became the framework within which electrolyte and acid–base handling was later worked out and managed clinically. Clearance and tubular transport concepts carried directly into the physiology of sodium, potassium and hydrogen ion regulation.
Carried by Homer Smith.
Peritoneal Dialysis influenced by Hemodialysis as Chronic Care
Chronic hemodialysis established the model of repeated extracorporeal or indwelling-access treatment for end-stage kidney failure, and peritoneal dialysis developed as an alternative modality within that same chronic-care frame. The catheter and sterile fluid techniques that made peritoneal dialysis practical were pursued as a home-based counterpart to center hemodialysis.
Carried by Henry Tenckhoff.
Organ-Protective Pharmacotherapy influenced by Hemodialysis as Chronic Care
Long-term dialysis created a population living for years with residual and failing kidney function, which made the preservation of that function a clinical target. Organ-protective pharmacotherapy, notably blockade of the renin–angiotensin system, was tested and adopted to slow progression in exactly this chronic kidney disease population.
Immune-Mediated Glomerulonephritis influenced by Renal Pathology and Biopsy-Based Classification
Biopsy with immunofluorescence and electron microscopy made immune-mediated glomerular disease visible and classifiable, allowing distinct entities such as IgA nephropathy and anti-GBM disease to be defined by their deposits. The tissue classification gave the immunological theory its concrete disease categories.
Carried by Jean Berger.
Immune-Mediated Glomerulonephritis influenced by Clinical Syndromic Diagnosis
The clinical syndromes of nephritis and nephrotic syndrome, including the observation that some nephritis follows streptococcal infection, gave immunology a defined disease target. The immune reframing of glomerulonephritis took these syndromic entities as its starting cases.
CKD Staging and Epidemiology influenced by Organ-Protective Pharmacotherapy
The demonstration that progression of chronic kidney disease could be slowed by pharmacotherapy gave staging its clinical purpose: identifying patients early enough to treat. Staging and epidemiology were framed around when organ-protective treatment should begin.
Beyond the field
Where Nephrology's ideas came from in other fields, and what they led to there: the strongest 12 of 28 links.
Transplant Immunology and Immunosuppression influenced Advanced Heart Failure and Transplant Medicine in Cardiology
Transplant immunology and immunosuppression, developed in nephrology for kidney transplantation, provided the immunosuppressive regimens that made cardiac transplantation viable.
Transplant Immunology and Immunosuppression influenced Liver Transplantation in Gastroenterology And Hepatology
Transplant immunology and immunosuppression, developed through kidney transplantation and the introduction of azathioprine and corticosteroids, made liver grafting survive rejection and was the essential precondition for the first successful liver transplants.
Carried by Thomas Starzl; Roy Calne.
Filtration–Reabsorption Physiology influenced Physiological clearance and volume-of-distribution framework in Pharmacokinetics
Renal clearance as a pharmacokinetic parameter was modelled on the filtration-reabsorption physiology of the kidney, which described how solute is filtered and partly reabsorbed. That physiological scheme was taken over to define and measure drug clearance.
Immune-Mediated Glomerulonephritis influenced by Autoantibody-Based Autoimmune Disease Recognition in Autoimmunity
The ability to recognize autoantibodies was a direct advancement built upon earlier immunological and pathological discoveries.
Immune-Mediated Glomerulonephritis influenced by Immunochemistry and serological diagnosis in Clinical Immunology
Immunochemistry and serological diagnosis provided the necessary tools to identify specific immune components involved in disease.
Immune-Mediated Glomerulonephritis influenced Multisystem and Overlap Connective Tissue Disease in Rheumatology
Recognition that immune mechanisms produce glomerulonephritis supported the view that connective tissue diseases are systemic immune disorders affecting multiple organs.
Transplant Immunology and Immunosuppression influenced Operational Tolerance Induction in Transplant Surgery
Clinical transplant immunosuppression provided the patient populations and assay methods on which operational tolerance induction protocols were tested.
Transplant Immunology and Immunosuppression influenced Biologic and targeted immunotherapy in Clinical Immunology
Transplant immunology's work on immunosuppression and antibody-mediated rejection informed the development of biologic immunosuppressants and targeted antibody therapies.
Transplant Immunology and Immunosuppression influenced Kidney paired donation in Market Design
Paired donation is driven by the immunology of donor-recipient compatibility: HLA and blood-group matching rules from transplant immunology define which pairs are incompatible and therefore need to be exchanged in a swap.
Transplant Immunology and Immunosuppression influenced Brain Death and the Dead Donor Rule in Transplant Surgery
The need for viable organs for transplantation under immunosuppression drove the redefinition of death by neurological criteria, since cadaver organs had to be removed while circulation was still supported.
Transplant Immunology and Immunosuppression influenced by Immunochemistry and serological diagnosis in Clinical Immunology
Immunochemistry and serology gave transplant immunology its methods for detecting and typing antigens, notably the leukocyte agglutination and cytotoxicity tests used to define HLA types for matching.
Transplant Immunology and Immunosuppression influenced by Transplantation in Surgery
Clinical organ transplantation, beginning with the Boston kidney graft between identical twins in 1954, posed the rejection problem that transplant immunology was built to explain and suppress.
Carried by Joseph Murray.

Nephrology is a planet in Nousfarer
Its city has a tower for each of these 10 frameworks. Land, walk in, and climb one concept at a time.
Land on NephrologyRelated fields
Fields its ideas are linked to
- Clinical Immunology 3 links
- Transplant Surgery 3 links
- Cardiology 2 links
- Urology 2 links
- Physiology 1 link
- Biomedical Engineering 1 link
- Separation Processes 1 link
- Market Design 1 link
- Endocrinology And Diabetes 1 link
- Gastroenterology And Hepatology 1 link
- Rheumatology 1 link
- Evidence Based Medicine 1 link